LobbyingUc Health lobbying by quarter
Uc Health's latest lobbying report covers Q2 2026, at $50K. The four quarters Q3 2025–Q2 2026 total $200K. Its first report covers Q4 2022; the issues it reports most are Medicare/Medicaid and Pharmacy.
Uc Health
- Latest quarter
- $50K
- Q2 2026 · 1 reports
- Last 12 months
- $200K
- Last 4 quarters
- vs last quarter
- 0.0%
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $77.5K | 2 |
| Q1 2023 | $77.5K | 2 |
| Q2 2023 | $77.5K | 2 |
| Q3 2023 | $77.5K | 2 |
| Q4 2023 | $77.5K | 2 |
| Q1 2024 | $90K | 2 |
| Q2 2024 | $90K | 2 |
| Q3 2024 | $50K | 1 |
| Q4 2024 | $50K | 1 |
| Q1 2025 | $50K | 1 |
| Q2 2025 | $50K | 1 |
| Q3 2025 | $50K | 1 |
| Q4 2025 | $50K | 1 |
| Q1 2026 | $50K | 1 |
| Q2 2026 | $50K | 1 |
Policy issues the reports name
- Medicare and Medicaid22 reports
- Pharmacy14 reports
- Health issues12 reports
- Defense11 reports
- Budget and appropriations4 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES22 reports
- SENATE22 reports
- Office of the Vice President of the United States3 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseUc Health | $687.5K | 15 quarters |
| Holland & Knight | $280K | 7 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| CANDACE LEIGH NOVAK SABERS | VP, Government Relations, UC Health | Q3 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/03for Q2 | In-house | $50K |
| 04/14for Q1 | In-house | $50K |
| 01/20for Q4 2025 | In-house | $50K |
| 25/10/08for Q3 2025 | In-house | $50K |
| 25/07/18for Q2 2025 | In-house | $50K |
| 25/04/17for Q1 2025 | In-house | $50K |
| 25/04/04for Q2 2025 | In-house | Under $5,000 |
| 25/04/04for Q2 2025 | In-house | Under $5,000 |
| 25/02/04for Q4 2024 | In-house | $50K |
| 24/10/18for Q3 2024 | In-house | $50K |
| 24/08/13for Q2 2024 | In-house | $50K |
| 24/07/05for Q2 2024 | Holland & Knight | $40K |
| 24/04/22for Q1 2024 | Holland & Knight | $40K |
| 24/04/22for Q1 2024 | In-house | $50K |
| 24/01/24for Q4 2023 | In-house | $37.5K |
| 24/01/22for Q4 2023 | Holland & Knight | $40K |
| 23/10/20for Q3 2023 | In-house | $37.5K |
| 23/10/19for Q3 2023 | Holland & Knight | $40K |
| 23/08/04for Q2 2023 | In-house | $37.5K |
| 23/07/19for Q2 2023 | Holland & Knight | $40K |